SEC Tracker
Get the app

Capricor Therapeutics CAPR

Capricor Therapeutics reported a $42.66 million net loss

Capricor Therapeutics (CAPR) filed a 10-Q with the SEC on Nov 10, 2026, 5:26 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Major
  1. Net loss: $42.66 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.73 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $44.28 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Capricor Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

2 new risk factors · 3 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$44.68M−$42.95M−4%
Net income−$42.66M−$40.73M−4.7%
Operating cash flow−$35.69M−$31.49M−13%
Cash$44.28M$20.94M+112%
New risk factors (2)
  • In the arbitration, Capricor counterclaimed for breach of contract (repudiation and failure to perform), breach of the implied covenant of good faith and fair dealing, rescission based on mutual mistake, declaration of Capricor's right to distribute Deramiocel, and unjust enrichment, reserving claims for unilateral…
  • We are building commercial capabilities and a corporate compliance program in preparation for the potential launch of Deramiocel, and we may be unable to do so effectively, on a timely basis or at all. +1 more paragraph
New legal mentions (3)
  • Capricor subsequently withdrew the motion, without prejudice, in order to resolve the dispute through arbitration, and arbitration proceedings have commenced (see Note 15 – "Commitments and Contingencies").
  • In the arbitration, NS filed a complaint for Breach of Contract against Capricor and demands declaratory and injunctive relief holding that Capricor breached the Distribution Agreement, that the Distribution Agreement remains in full force and effect, and requiring Capricor to perform its obligations thereunder. +2 more paragraphs
  • On September 28, 2026 Robert Novick filed a putative securities class action in the Southern District of California against Capricor, its Chief Executive Officer and its Chief Financial Officer, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 thereunder. +1 more paragraph

Data on this page was fetched . The filing on SEC.gov is the record.